Magnetic resonance imaging as a potential biomarker for Parkinson's disease

Translational Research

Volumn 175, Issue , 2016, Pages 4-16

  Tuite, Paul ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; NEUROMELANIN; BIOLOGICAL MARKER; GLUTATHIONE;

DIFFUSION TENSOR IMAGING; FUNCTIONAL CONNECTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; MOLECULAR IMAGING; MULTICENTER STUDY (TOPIC); NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE SUSCEPTIBILITY MAPPING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCINTIGRAPHY; SUSCEPTIBILITY WEIGHTED IMAGING; TRACTOGRAPHY; VOXEL BASED MORPHOMETRY; METABOLISM; NEUROCHEMISTRY; PERFUSION; PROCEDURES;

BIOMARKERS; GLUTATHIONE; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROCHEMISTRY; PARKINSON DISEASE; PERFUSION;

EID: 84969915674     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.12.006     Document Type: Review

References (157)

1. 1 Delenclos, M., Jones, D.R., McLean, P.J., Uitti, R.J., Biomarkers in Parkinson's disease: advances and strategies. Parkinsonism Relat Disord 22:suppl 1 (2015), S106–S110.
2. 2 Braak, H., Bohl, J.R., Müller, C.M., Rüb, U., de Vos, R.A., Del Tredici, K., Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 21 (2006), 2042–2051.
3. 3 Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A., Jansen Steur, E.N., Braak, E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003), 197–211.
4. 4 Frost, B., Diamond, M.I., Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11 (2010), 155–159.
5. 5 Jucker, M., Walker, L.C., Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501 (2013), 45–51.
6. 6 Luk, K.C., Kehm, V., Carroll, J., et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 (2012), 949–953.
7. 7 Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 136:Pt 4 (2013), 1128–1138.
8. 8 Warren, J.D., Rohrer, J.D., Schott, J.M., Fox, N.C., Hardy, J., Rossor, M.N., Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends Neurosci 36 (2013), 561–569.
9. 9 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001), 89–95.
10. 10 Blennow, K., Hampel, H., Weiner, M., Zetterberg, H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6 (2010), 131–144.
11. 11 Arena, J.E., Stoessl, A.J., Optimizing diagnosis in Parkinson's disease: radionuclide imaging. Parkinsonism Relat Disord 22 Suppl 1 (2016), S47–S51.
12. 12 Volc, D., Hendrix, S., Thun-Hohenstein, C., et al. Results from a phase I study to assess the tolerability, safety and immunological and clinical activity of affitope PD01A in patients with early Parkinson's disease. Neurodegener Dis, 15, 2015, 1317.
13. 13 Lehericy, S., Sharman, M.A., Dos Santos, C.L., Paquin, R., Gallea, C., Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord 27 (2012), 822–830.
14. 14 Schuster, C., Elamin, M., Hardiman, O., Bede, P., Presymptomatic and longitudinal neuroimaging in neurodegeneration—from snapshots to motion picture: a systematic review. J Neurol Neurosurg Psychiatry 86 (2015), 1089–1096.
15. 15 Ofori, E., Du, G., Babcock, D., Huang, X., Vaillancourt, D.E., Parkinson's disease biomarkers program brain imaging repository. Neuroimage 124:Pt B (2015), 1120–1124.
16. 16 Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J., Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 (1992), 181–184.
17. 17 Kalia, L.V., Lang, A.E., Parkinson's disease. Lancet 386 (2015), 896–912.
18. 18 Petrou, M., Dwamena, B.A., Foerster, B.R., et al. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord 30 (2015), 928–935.
19. 19 Marek, K., Seibyl, J., Eberly, S., et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 82 (2014), 1791–1797.
20. 20 Halliday, G.M., Holton, J.L., Revesz, T., Dickson, D.W., Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122 (2011), 187–204.
21. 21 Boeve, B.F., Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol 12 (2013), 469–482.
22. 22 Scherfler, C., Frauscher, B., Schocke, M., et al. White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 69 (2011), 400–407.
23. 23 Ellmore, T.M., Castriotta, R.J., Hendley, K.L., et al. Altered nigrostriatal and nigrocortical functional connectivity in rapid eye movement sleep behavior disorder. Sleep 36 (2013), 1885–1892.
24. 24 Hanyu, H., Inoue, Y., Sakurai, H., et al. Voxel-based magnetic resonance imaging study of structural brain changes in patients with idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord 18 (2012), 136–139.
25. 25 Marras, C., Subtypes of Parkinson's disease: state of the field and future directions. Curr Opin Neurol 28 (2015), 382–386.
26. 26 Lawton, M., Baig, F., Rolinski, M., et al. Parkinson's disease subtypes in the Oxford Parkinson Disease Centre (OPDC) discovery cohort. J Parkinsons Dis 5 (2015), 269–279.
27. 27 Ascherio, A., LeWitt, P.A., Xu, K., et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66 (2009), 1460–1468.
28. 28 Schwarzschild, M.A., Schwid, S.R., Marek, K., et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65 (2008), 716–723.
29. 29 Rosenthal, L.S., Drake, D., Alcalay, R.N., et al. The NINDS Parkinson's disease biomarkers program. Mov Disord, 2015 http://dx.doi.org/10.1002/mds.26438. [Epub ahead of print].
30. 30 Campbell, M.C., Koller, J.M., Snyder, A.Z., Buddhala, C., Kotzbauer, P.T., Perlmutter, J.S., CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology 84 (2015), 2413–2421.
31. 31 McKeown, M.J., Peavy, G.M., Biomarkers in Parkinson disease: it's time to combine. Neurology 84 (2015), 2392–2393.
32. 32 Zeighami, Y., Ulla, M., Iturria-Medina, Y., et al. Network structure of brain atrophy in de novo Parkinson's disease. Elife, 4, 2015.
33. 33 The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95 (2011), 629–635.
34. 34 Pyatigorskaya, N., Gallea, C., Garcia-Lorenzo, D., Vidailhet, M., Lehericy, S., A review of the use of magnetic resonance imaging in Parkinson's disease. Ther Adv Neurol Disord 7 (2014), 206–220.
35. 35 Stoessl, A.J., Lehericy, S., Strafella, A.P., Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. Lancet 384 (2014), 532–544.
36. 36 Tuite, P.J., Mangia, S., Michaeli, S., Magnetic resonance imaging (MRI) in Parkinson's disease. J Alzheimers Dis Parkinsonism(suppl 1), 2013, 001.
37. 37 Gorell, J.M., Ordidge, R.J., Brown, G.G., Deniau, J.C., Buderer, N.M., Helpern, J.A., Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45 (1995), 1138–1143.
38. 38 Martin, W.R., Wieler, M., Gee, M., Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70:16 Pt 2 (2008), 1411–1417.
39. 39 Rossi, M.E., Ruottinen, H., Saunamaki, T., Elovaara, I., Dastidar, P., Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages. Acad Radiol 21 (2014), 64–71.
40. 40 Ulla, M., Bonny, J.M., Ouchchane, L., Rieu, I., Claise, B., Durif, F., Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. PLoS One, 8, 2013, e57904.
41. 41 Wieler, M., Gee, M., Martin, W.R., Longitudinal midbrain changes in early Parkinson's disease: iron content estimated from R2*/MRI. Parkinsonism Relat Disord 21 (2015), 179–183.
42. 42 Ward, R.J., Zucca, F.A., Duyn, J.H., Crichton, R.R., Zecca, L., The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13 (2014), 1045–1060.
43. 43 Grolez, G., Moreau, C., Sablonniere, B., et al. Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease. BMC Neurol, 15, 2015, 74.
44. 44 He, N., Ling, H., Ding, B., et al. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping. Hum Brain Mapp 36 (2015), 4407–4420.
45. 45 Du, G., Lewis, M.M., Styner, M., et al. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 26 (2011), 1627–1632.
46. 46 Barbosa, J.H., Santos, A.C., Tumas, V., et al. Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2. Magn Reson Imaging 33 (2015), 559–565.
47. 47 Reiter, E., Mueller, C., Pinter, B., et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Mov Disord 30 (2015), 1068–1076.
48. 48 Schwarz, S.T., Afzal, M., Morgan, P.S., Bajaj, N., Gowland, P.A., Auer, D.P., The ‘swallow tail’ appearance of the healthy nigrosome—a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One, 9, 2014, e93814.
49. 49 Blazejewska, A.I., Schwarz, S.T., Pitiot, A., et al. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology 81 (2013), 534–540.
50. 50 Mueller, C., Pinter, B., Reiter, E., et al. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. Neurology, 82, 2014, 1752.
51. 51 Cho, Z.H., Min, H.K., Oh, S.H., et al. Direct visualization of deep brain stimulation targets in Parkinson disease with the use of 7-tesla magnetic resonance imaging. J Neurosurg 113 (2010), 639–647.
52. 52 Lehericy, S., Bardinet, E., Poupon, C., Vidailhet, M., Francois, C., 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Mov Disord 29 (2014), 1574–1581.
53. 53 Péran, P., Cherubini, A., Assogna, F., et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 133 (2010), 3423–3433.
54. 54 Balaban, R.S., Ceckler, T.L., Magnetization transfer contrast in magnetic resonance imaging. Magn Reson Q 8 (1992), 116–137.
55. 55 Mangia, S., De Martino, F., Liimatainen, T., Garwood, M., Michaeli, S., Magnetization transfer using inversion recovery during off-resonance irradiation. Magn Reson Imaging 29 (2011), 1346–1350.
56. 56 Tambasco, N., Belcastro, V., Sarchielli, P., et al. A magnetization transfer study of mild and advanced Parkinson's disease. Eur J Neurol 18 (2011), 471–477.
57. 57 Eckert, T., Sailer, M., Kaufmann, J., et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 21 (2004), 229–235.
58. 58 Anik, Y., Iseri, P., Demirci, A., Komsuoglu, S., Inan, N., Magnetization transfer ratio in early period of Parkinson disease. Acad Radiol 14 (2007), 189–192.
59. 59 Morgen, K., Sammer, G., Weber, L., et al. Structural brain abnormalities in patients with Parkinson disease: a comparative voxel-based analysis using T1-weighted MR imaging and magnetization transfer imaging. AJNR Am J Neuroradiol 32 (2011), 2080–2086.
60. 60 Tambasco, N., Pelliccioli, G.P., Chiarini, P., et al. Magnetization transfer changes of grey and white matter in Parkinson's disease. Neuroradiology 45 (2003), 224–230.
61. 61 Tuite, P.J., Mangia, S., Tyan, A.E., Lee, M.K., Garwood, M., Michaeli, S., Magnetization transfer and adiabatic R 1rho MRI in the brainstem of Parkinson's disease. Parkinsonism Relat Disord 18 (2012), 623–625.
62. 62 Padovani, A., Borroni, B., Brambati, S.M., et al. Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 77 (2006), 457–463.
63. 63 Hussl, A., Mahlknecht, P., Scherfler, C., et al. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. Mov Disord 25 (2010), 2444–2449.
64. 64 Massey, L.A., Jager, H.R., Paviour, D.C., et al. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology 80 (2013), 1856–1861.
65. 65 Brooks, D.J., Seppi, K., Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 24 (2009), 949–964.
66. 66 Meijer, F.J., Bloem, B.R., Mahlknecht, P., Seppi, K., Goraj, B., Update on diffusion MRI in Parkinson's disease and atypical parkinsonism. J Neurol Sci 332 (2013), 21–29.
67. 67 Seppi, K., Schocke, M.F., Esterhammer, R., et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 60 (2003), 922–927.
68. 68 Seppi, K., Schocke, M.F., Prennschuetz-Schuetzenau, K., et al. Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord 21 (2006), 847–852.
69. 69 Wadia, P.M., Howard, P., Ribeirro, M.Q., et al. The value of GRE, ADC and routine MRI in distinguishing Parkinsonian disorders. Can J Neurol Sci 40 (2013), 389–402.
70. 70 Meijer, F.J., van Rumund, A., Fasen, B.A., et al. Susceptibility-weighted imaging improves the diagnostic accuracy of 3T brain MRI in the work-up of parkinsonism. AJNR Am J Neuroradiol 36 (2015), 454–460.
71. 71 Tessa, C., Lucetti, C., Giannelli, M., et al. Progression of brain atrophy in the early stages of Parkinson's disease: a longitudinal tensor-based morphometry study in de novo patients without cognitive impairment. Hum Brain Mapp 35 (2014), 3932–3944.
72. 72 Duncan, G.W., Firbank, M.J., O'Brien, J.T., Burn, D.J., Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease?. Mov Disord 28 (2013), 425–438.
73. 73 Song, S.K., Lee, J.E., Park, H.J., Sohn, Y.H., Lee, J.D., Lee, P.H., The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 26 (2011), 289–296.
74. 74 Kostic, V.S., Agosta, F., Petrovic, I., et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology 75 (2010), 857–863.
75. 75 Feldmann, A., Illes, Z., Kosztolanyi, P., et al. Morphometric changes of gray matter in Parkinson's disease with depression: a voxel-based morphometry study. Mov Disord 23 (2008), 42–46.
76. 76 Garg, A., Appel-Cresswell, S., Popuri, K., McKeown, M.J., Beg, M.F., Morphological alterations in the caudate, putamen, pallidum, and thalamus in Parkinson's disease. Front Neurosci, 9, 2015, 101.
77. 77 Nemmi, F., Sabatini, U., Rascol, O., Peran, P., Parkinson's disease and local atrophy in subcortical nuclei: insight from shape analysis. Neurobiol Aging 36 (2015), 424–433.
78. 78 Cho, Z.H., Oh, S.H., Kim, J.M., et al. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging. Mov Disord 26 (2011), 713–718.
79. 79 Summerfield, C., Junque, C., Tolosa, E., et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 62 (2005), 281–285.
80. 80 Beyer, M.K., Janvin, C.C., Larsen, J.P., Aarsland, D., A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 78 (2007), 254–259.
81. 81 Baudrexel, S., Seifried, C., Penndorf, B., et al. The value of putaminal diffusion imaging versus 18-fluorodeoxyglucose positron emission tomography for the differential diagnosis of the Parkinson variant of multiple system atrophy. Mov Disord 29 (2014), 380–387.
82. 82 Gupta, D., Saini, J., Kesavadas, C., Sarma, P.S., Kishore, A., Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology 52 (2010), 1087–1094.
83. 83 Wang, Y., Butros, S.R., Shuai, X., et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol 33 (2012), 266–273.
84. 84 Zucca, F.A., Segura-Aguilar, J., Ferrari, E., et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and parkinson's disease. Prog Neurobiol, 2015 http://dx.doi.org/10.1016/j.pneurobio.2015.09.012. [Epub ahead of print].
85. 85 Castellanos, G., Fernandez-Seara, M.A., Lorenzo-Betancor, O., et al. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Mov Disord 30 (2015), 945–952.
86. 86 Sasaki, M., Shibata, E., Tohyama, K., et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 17 (2006), 1215–1218.
87. 87 Schwarz, S.T., Rittman, T., Gontu, V., Morgan, P.S., Bajaj, N., Auer, D.P., T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord 26 (2011), 1633–1638.
88. 88 Kashihara, K., Shinya, T., Higaki, F., Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosci 18 (2011), 1093–1096.
89. 89 Ogisu, K., Kudo, K., Sasaki, M., et al. 3D Neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease. Neuroradiology 55 (2013), 719–724.
90. 90 Ohtsuka, C., Sasaki, M., Konno, K., et al. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging. Neurosci Lett 541 (2013), 93–98.
91. 91 Garcia-Lorenzo, D., Longo-Dos Santos, C., Ewenczyk, C., et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain 136 (2013), 2120–2129 England.
92. 92 Reimao, S., Pita Lobo, P., Neutel, D., et al. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease. Mov Disord 30 (2015), 953–959.
93. 93 Michaeli, S., Oz, G., Sorce, D.J., et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 22 (2007), 334–340.
94. 94 Michaeli, S., Sorce, D., Garwood, M., T2rho and T1rho adiabatic relaxations and contrasts. Curr Anal Chem 4 (2008), 8–25.
95. 95 Nestrasil, I., Michaeli, S., Liimatainen, T., et al. T1rho and T2rho MRI in the evaluation of Parkinson's disease. J Neurol 257 (2010), 964–968.
96. 96 Boeve, B.F., Predicting the future in idiopathic rapid-eye movement sleep behaviour disorder. Lancet Neurol 9 (2010), 1040–1042.
97. 97 Boeve, B.F., REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 1184 (2010), 15–54.
98. 98 Mangia S, Burton P, Svatkova A, et al. MRI signatures of the brain of PD and iRBD subjects. ISMRM 24th Annual Meeting 07–13. May 2016; 2016; Singapore.
99. Le Bihan, D., Breton, E., Lallemand, D., Grenier, P., Cabanis, E., Laval-Jeantet, M., MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161 (1986), 401–407.
100. Le Bihan, D., Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci 4 (2003), 469–480.
101. 101 Chan, L.L., Rumpel, H., Yap, K., et al. Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry 78 (2007), 1383–1386.
102. 102 Vaillancourt, D.E., Spraker, M.B., Prodoehl, J., et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 72 (2009), 1378–1384.
103. 103 Yoshikawa, K., Nakata, Y., Yamada, K., Nakagawa, M., Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry 75 (2004), 481–484.
104. 104 Zhan, W., Kang, G.A., Glass, G.A., et al. Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging. Mov Disord 27 (2012), 90–97.
105. 105 Wang, J.J., Lin, W.Y., Lu, C.S., et al. Parkinson disease: diagnostic utility of diffusion kurtosis imaging. Radiology 261 (2011), 210–217.
106. 106 Menke, R.A., Jbabdi, S., Miller, K.L., Matthews, P.M., Zarei, M., Connectivity-based segmentation of the substantia Nigra in human and its implications in Parkinson's disease. Neuroimage 52 (2010), 1175–1180.
107. 107 Schwarz, S.T., Abaei, M., Gontu, V., Morgan, P.S., Bajaj, N., Auer, D.P., Diffusion tensor imaging of nigral degeneration in Parkinson's disease: a region-of-interest and voxel-based study at 3 T and systematic review with meta-analysis. Neuroimage Clin 3 (2013), 481–488.
108. 108 Ziegler, E., Rouillard, M., Andre, E., et al. Mapping track density changes in nigrostriatal and extranigral pathways in Parkinson's disease. Neuroimage 99 (2014), 498–508.
109. 109 Kamagata, K., Motoi, Y., Abe, O., et al. White matter alteration of the cingulum in Parkinson disease with and without dementia: evaluation by diffusion tensor tract-specific analysis. AJNR Am J Neuroradiol 33 (2012), 890–895.
110. 110 Prodoehl, J., Li, H., Planetta, P.J., et al. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord 28 (2013), 1816–1822.
111. 111 Ibarretxe-Bilbao, N., Junque, C., Marti, M.J., Tolosa, E., Brain structural MRI correlates of cognitive dysfunctions in Parkinson's disease. J Neurol Sci 310 (2011), 70–74.
112. 112 Ibarretxe-Bilbao, N., Junque, C., Marti, M.J., et al. Olfactory impairment in Parkinson's disease and white matter abnormalities in central olfactory areas: a voxel-based diffusion tensor imaging study. Mov Disord 25 (2010), 1888–1894.
113. 113 Ibarretxe-Bilbao, N., Tolosa, E., Junque, C., Marti, M.J., MRI and cognitive impairment in Parkinson's disease. Mov Disord 24:suppl 2 (2009), S748–S753.
114. 114 Rolheiser, T.M., Fulton, H.G., Good, K.P., et al. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease. J Neurol 258 (2011), 1254–1260.
115. 115 Ofori, E., Pasternak, O., Planetta, P.J., et al. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease. Brain 138:Pt 8 (2015), 2322–2331.
116. 116 Menke, R.A., Scholz, J., Miller, K.L., et al. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage 47 (2009), 435–441.
117. 117 Schuff, N., Wu, I.W., Buckley, S., et al. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Mov Disord 30 (2015), 1885–1892.
118. 118 Sharman, M., Valabregue, R., Perlbarg, V., et al. Parkinson's disease patients show reduced cortical-subcortical sensorimotor connectivity. Mov Disord 28 (2013), 447–454.
119. 119 Zhang, Y., Wu, I.W., Buckley, S., et al. Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease. Mov Disord 30 (2015), 1229–1236.
120. 120 Griffanti, L., Rolinski, M., Szewczyk-Krolikowski, K., et al. Challenges in the reproducibility of clinical studies with resting state fMRI: an example in early Parkinson's disease. Neuroimage 124:Pt A (2015), 704–713.
121. 121 Wu, T., Wang, L., Hallett, M., Chen, Y., Li, K., Chan, P., Effective connectivity of brain networks during self-initiated movement in Parkinson's disease. Neuroimage 55 (2011), 204–215.
122. 122 Wu, T., Long, X., Zang, Y., et al. Regional homogeneity changes in patients with Parkinson's disease. Hum Brain Mapp 30 (2009), 1502–1510.
123. 123 Kwak, Y., Peltier, S., Bohnen, N.I., Müller, M.L., Dayalu, P., Seidler, R.D., Altered resting state cortico-striatal connectivity in mild to moderate stage Parkinson's disease. Front Syst Neurosci, 4, 2010, 143.
124. 124 Baudrexel, S., Witte, T., Seifried, C., et al. Resting state fMRI reveals increased subthalamic nucleus-motor cortex connectivity in Parkinson's disease. Neuroimage 55 (2011), 1728–1738.
125. 125 Skidmore, F.M., Yang, M., Baxter, L., et al. Reliability analysis of the resting state can sensitively and specifically identify the presence of Parkinson disease. Neuroimage 75 (2013), 249–261.
126. 126 Krajcovicova, L., Mikl, M., Marecek, R., Rektorova, I., The default mode network integrity in patients with Parkinson's disease is levodopa equivalent dose-dependent. J Neural Transm 119 (2012), 443–454.
127. 127 Rolinski, M., Griffanti, L., Szewczyk-Krolikowski, K., et al. Aberrant functional connectivity within the basal ganglia of patients with Parkinson's disease. Neuroimage Clin 8 (2015), 126–132.
128. 128 Skidmore, F.M., Yang, M., Baxter, L., et al. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. Neuroimage 81 (2013), 484–495.
129. 129 Festini, S.B., Bernard, J.A., Kwak, Y., et al. Altered cerebellar connectivity in Parkinson's patients ON and OFF L-DOPA medication. Front Hum Neurosci, 9, 2015, 214.
130. 130 Kwak, Y., Peltier, S.J., Bohnen, N.I., Muller, M.L., Dayalu, P., Seidler, R.D., L-DOPA changes spontaneous low-frequency BOLD signal oscillations in Parkinson's disease: a resting state fMRI study. Front Syst Neurosci, 6, 2012, 52.
131. 131 Monchi, O., Petrides, M., Mejia-Constain, B., Strafella, A.P., Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain 130:Pt 1 (2007), 233–244.
132. 132 Rieckmann, A., Gomperts, S.N., Johnson, K.A., Growdon, J.H., Van Dijk, K.R., Putamen-midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases. Neuroimage Clin 8 (2015), 554–559.
133. 133 Schuff, N., Potential role of high-field MRI for studies in Parkinson's disease. Mov Disord 24:suppl 2 (2009), S684–S690.
134. 134 Fernandez-Seara, M.A., Mengual, E., Vidorreta, M., et al. Resting state functional connectivity of the subthalamic nucleus in Parkinson's disease assessed using arterial spin-labeled perfusion fMRI. Hum Brain Mapp 36 (2015), 1937–1950.
135. 135 Kamagata, K., Motoi, Y., Hori, M., et al. Posterior hypoperfusion in Parkinson's disease with and without dementia measured with arterial spin labeling MRI. J Magn Reson Imaging 33 (2011), 803–807.
136. 136 Teune, L.K., Renken, R.J., de Jong, B.M., et al. Parkinson's disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET imaging. Neuroimage Clin 5 (2014), 240–244.
137. 137 Le Heron, C.J., Wright, S.L., Melzer, T.R., et al. Comparing cerebral perfusion in Alzheimer's disease and Parkinson's disease dementia: an ASL-MRI study. J Cereb Blood Flow Metab 34 (2014), 964–970.
138. 138 Black, K.J., Koller, J.M., Campbell, M.C., Gusnard, D.A., Bandak, S.I., Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci 30 (2010), 16284–16292.
139. 139 Stewart, S.B., Koller, J.M., Campbell, M.C., Black, K.J., Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI. Peer J, 2, 2014, e687.
140. 140 Andersen, A.H., Hardy, P.A., Forman, E., et al. Pharmacologic MRI (phMRI) as a tool to differentiate Parkinson's disease-related from age-related changes in basal ganglia function. Neurobiol Aging 36 (2015), 1174–1182.
141. 141 Oz, G., Terpstra, M., Tkác, I., et al. Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med 55 (2006), 296–301.
142. 142 Oz, G., MR spectroscopy: a longitudinal biomarker for substantia nigra pathology in Parkinson's disease?. Mov Disord 30 (2015), 1304–1305.
143. 143 Seraji-Bozorgzad, N., Bao, F., George, E., et al. Longitudinal study of the substantia nigra in Parkinson disease: a high-field (1) H-MR spectroscopy imaging study. Mov Disord 30 (2015), 1400–1404.
144. 144 Emir, U.E., Tuite, P.J., Oz, G., Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PLoS One, 7, 2012, e30918.
145. 145 Pearce, R.K., Owen, A., Daniel, S., Jenner, P., Marsden, C.D., Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104 (1997), 661–677.
146. 146 Holmay, M.J., Terpstra, M., Coles, L.D., et al. N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol 36 (2013), 103–106.
147. 147 Coles, L.D., Terpstra, M., Oz, G., et al. Repeated-dose oral N-acetylcysteine: pharmacokinetics and effect on brain glutathione. Mov Disord, 30, 2015, e10.
148. 148 Mischley, L.K., Leverenz, J.B., Lau, R.C., et al. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease. Mov Disord 30 (2015), 1696–1701.
149. 149 Mazuel, L., Chassain, C., Jean, B., et al. Proton MR spectroscopy for diagnosis and evaluation of treatment efficacy in Parkinson disease. Radiology, 2015, 142764 [Epub ahead of print].
150. 150 Franco-Iborra, S., Vila, M., Perier, C., The Parkinson disease mitochondrial hypothesis: where are we at?. Neuroscientist, 2015 [Epub ahead of print].
151. 151 Weiduschat, N., Mao, X., Beal, M.F., Nirenberg, M.J., Shungu, D.C., Henchcliffe, C., Sex differences in cerebral energy metabolism in Parkinson's disease: a phosphorus magnetic resonance spectroscopic imaging study. Parkinsonism Relat Disord 20 (2014), 545–548.
152. 152 Weiduschat, N., Mao, X., Beal, M.F., Nirenberg, M.J., Shungu, D.C., Henchcliffe, C., Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease. J Neuroimaging 25 (2015), 105–110.
153. 153 Du, F., Zhu, X.H., Zhang, Y., et al. Tightly coupled brain activity and cerebral ATP metabolic rate. Proc Natl Acad Sci U S A 105 (2008), 6409–6414.
154. 154 Mortiboys, H., Aasly, J., Bandmann, O., Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain 136:Pt 10 (2013), 3038–3050.
155. 155 Zhu, X.-H., Lee, B.-Y., Rolandelli, S., Tuite, P., Chen, W., Abnormal occipital metabolism in mild-moderate Parkinson's disease revealed by in vivo 31P-MRS at 7T. Mov Disord, 29, 2014, e2.
156. 156 Mortiboys, H., Furmston, R., Bronstad, G., Aasly, J., Elliott, C., Bandmann, O., UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2G2019S carriers and in vivo. Neurology 85 (2015), 846–852.
157. 157 Parry, G.J., Rodrigues, C.M., Aranha, M.M., et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol 33 (2010), 17–21.